Medical device company Integra LifeSciences (NASDAQ: IART) met Wall Street’s revenue expectations in Q3 2026, with sales up 2.3% year on year to $411.2 million. On the other hand, next quarter’s revenue guidance of $423 million was less impressive, coming in 2.4% below analysts’ estimates. Its non-GAAP profit of $0.59 per share was 5.5% above analysts’ consensus estimates.
Is now the time to buy Integra LifeSciences? Find out by accessing our full research report, it’s free.
Integra LifeSciences (IART) Q3 2026 Highlights:
- Revenue: $411.2 million vs analyst estimates of $412.6 million (2.3% year-on-year growth, in line)
- Adjusted EPS: $0.59 vs analyst estimates of $0.56 (5.5% beat)
- Adjusted EBITDA: $79.79 million vs analyst estimates of $83.25 million (19.4% margin, 4.2% miss)
- Revenue Guidance for Q4 2026 is $423 million at the midpoint, below analyst estimates of $433.2 million
- Management lowered its full-year Adjusted EPS guidance to $2.35 at the midpoint, a 4.1% decrease
- Operating Margin: 4.6%, down from 9.9% in the same quarter last year
- Free Cash Flow Margin: 20.8%, up from 6.4% in the same quarter last year
- Organic Revenue rose 2.5% year on year (miss)
- Market Capitalization: $1.04 billion
"Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing," said Stuart Essig, Chairman and Chief Executive Officer.
Company Overview
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Revenue Growth
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Regrettably, Integra LifeSciences’s sales grew at a tepid 1.7% compounded annual growth rate over the last five years. This fell short of our benchmarks and is a tough starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Integra LifeSciences’s annualized revenue growth of 2.9% over the last two years is above its five-year trend, which is encouraging. 
Integra LifeSciences also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Integra LifeSciences’s organic revenue averaged 1.3% year-on-year growth. Because this number is lower than its two-year revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results. 
This quarter, Integra LifeSciences grew its revenue by 2.3% year on year, and its $411.2 million of revenue was in line with Wall Street’s estimates. Company management is currently guiding for a 2.7% year-on-year decline in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 1.8% over the next 12 months, similar to its two-year rate. This projection doesn’t excite us and implies its products and services will see some demand headwinds.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.
Integra LifeSciences has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 18.9%.
Analyzing the trend in its profitability, Integra LifeSciences’s adjusted operating margin decreased by 8.6 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 2.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
In Q3, Integra LifeSciences generated an adjusted operating margin profit margin of 4.6%, down 12.1 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Sadly for Integra LifeSciences, its EPS declined by 4.5% annually over the last five years while its revenue grew by 1.7%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
Diving into the nuances of Integra LifeSciences’s earnings can give us a better understanding of its performance. As we mentioned earlier, Integra LifeSciences’s adjusted operating margin declined by 8.6 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q3, Integra LifeSciences reported adjusted EPS of $0.59, up from $0.54 in the same quarter last year. This print beat analysts’ estimates by 5.5%. Over the next 12 months, Wall Street expects Integra LifeSciences’s full-year EPS to stay about the same, moving from $2.52 to $2.53.
Key Takeaways from Integra LifeSciences’s Q3 Results
It was good to see Integra LifeSciences beat analysts’ EPS expectations this quarter. On the other hand, its revenue guidance for next quarter missed and its EPS guidance for next quarter fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 2.5% to $13 immediately following the results.
Integra LifeSciences underperformed this quarter, but does that create an opportunity to invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
